Hussein Laljee is an accomplished executive leader in Patient Safety with a career at Gilead Sciences spanning from January 2005 to the present. Currently serving as the Head of Benefit-Risk Science & Established Products, Laljee oversees three key teams focused on benefit-risk management, aggregate reports, and established products across various therapeutic areas, including Virology and Oncology. Previous roles include Executive Director positions in Medical Safety Science, where Laljee managed global surveillance, analytics, and risk management for multiple therapeutic areas, and held senior positions in signal detection and risk management. Prior experience includes a role at Merck Sharp & Dohme and leadership in pharmacovigilance at PPD Development. Laljee holds a BPharm from King's College London and a PhD in Pharmaceutical Chemistry from the University of Bradford.
This person is not in any teams
This person is not in any offices